MYOV
Price:
$26.98
Market Cap:
$2.62B
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was ...[Read more]
Industry
Biotechnology
IPO Date
2016-10-27
Stock Exchange
NYSE
Ticker
MYOV
According to Myovant Sciences Ltd.’s latest financial reports and current stock price. The company's current ROE is 49.79%. This represents a change of 451.25% compared to the average of 9.03% of the last 4 quarters.
The mean historical ROE of Myovant Sciences Ltd. over the last ten years is -908.43%. The current 49.79% ROE has changed -105.48% with respect to the historical average. Over the past ten years (40 quarters), MYOV's ROE was at its highest in in the June 2016 quarter at 220.64%. The ROE was at its lowest in in the March 2019 quarter at -1730.83%.
Average
-908.43%
Median
0%
Minimum
-6311.74%
Maximum
266.90%
Discovering the peaks and valleys of Myovant Sciences Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.56%
Maximum Annual ROE = 266.90%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -6311.74%
Year | ROE | Change |
---|---|---|
2022 | 43.50% | -39.64% |
2021 | 72.08% | -72.99% |
2020 | 266.90% | -104.23% |
2019 | -6311.74% | 1.56% |
2018 | -379.69% | 658.92% |
2017 | -50.03% | -Infinity% |
The current ROE of Myovant Sciences Ltd. (MYOV) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
127.49%
5-year avg
-1261.79%
10-year avg
-908.43%
Myovant Sciences Ltd.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Myovant Sciences Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Myovant Sciences Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Myovant Sciences Ltd.'s ROE?
How is the ROE calculated for Myovant Sciences Ltd. (MYOV)?
What is the highest ROE for Myovant Sciences Ltd. (MYOV)?
What is the 3-year average ROE for Myovant Sciences Ltd. (MYOV)?
What is the 5-year average ROE for Myovant Sciences Ltd. (MYOV)?
How does the current ROE for Myovant Sciences Ltd. (MYOV) compare to its historical average?